Friedreich Ataxia
A progressive autosomal recessive neurodegenerative disease causing ataxia, sensory loss, and severe hypertrophic cardiomyopathy, driven by a GAA expansion in the FXN gene.
Emergency Management: New-onset atrial fibrillation or ventricular arrhythmias require immediate cardioversion and anti-arrhythmic management.
Friedreich ataxia is an autosomal recessive, neurodegenerative disorder caused by a GAA trinucleotide repeat expansion in the FXN gene. It primarily affects the spinal cord, peripheral nerves, and cerebellum, leading to progressive ataxia, loss of deep tendon reflexes, and proprioceptive deficits, combined with hypertrophic cardiomyopathy.
Detailed Overview
As the most common hereditary ataxia, FRDA typically presents before age 25 with progressive gait instability and clumsiness. The genetic mutation results in profoundly reduced levels of frataxin, a mitochondrial protein involved in iron-sulfur cluster biosynthesis. This deficiency leads to mitochondrial dysfunction, oxidative stress, and cell death, primarily in the dorsal root ganglia, spinocerebellar tracts, dentate nucleus, and myocardium. Most patients become wheelchair-bound within 10-15 years of onset and often die from cardiac complications.
Epidemiology & Demographics
Prevalence is approximately 1 in 40,000 to 50,000 individuals of European descent. Carrier frequency is about 1 in 90 in these populations. It is exceptionally rare in Asian and African populations.
Etiological Mechanism
Autosomal recessive inheritance. Over 95% of patients have a homozygous GAA trinucleotide repeat expansion in intron 1 of the FXN gene on chromosome 9q21.11. Normal alleles have 5-33 repeats; disease-causing alleles have 66 to >1000 repeats.
Primary Causes
["Mutation in FXN gene (GAA repeat expansion or, rarely, a point mutation)."]
The GAA expansion causes epigenetic silencing and reduced transcription of the FXN gene, leading to frataxin deficiency. Frataxin is essential for assembling iron-sulfur clusters in the mitochondria. Lack of frataxin causes iron accumulation inside mitochondria, impaired ATP production, and high generation of reactive oxygen species (ROS). The resulting oxidative stress and energy failure selectively destroy neurons in the dorsal root ganglia, the posterior columns (loss of proprioception/vibration), the spinocerebellar tracts (ataxia), and the corticospinal tracts (weakness, Babinski sign). The myocardium is similarly affected, undergoing massive hypertrophy followed by fibrosis.
Diagnostic Criteria & Guidelines
Clinical presentation compatible with FRDA confirmed by genetic testing showing biallelic GAA repeat expansions in the FXN gene (or one expansion and one point mutation).
Recent FDA approval (2023): Omaveloxolone (Skyclarys) 150 mg PO once daily for patients 16 years and older; it activates Nrf2 pathways to reduce oxidative stress and slows clinical progression. Comprehensive multidisciplinary care is essential: physical therapy, speech therapy, and cardiology management.
Second-Line & Adjunctive Therapy
Management of complications: Beta-blockers (e.g., Metoprolol 25-50mg/day) and ACE inhibitors (e.g., Lisinopril 5-10mg/day) for cardiomyopathy. Insulin or oral hypoglycemics for diabetes. Antioxidant therapies like Idebenone (high dose, e.g., 900 mg/day) have been used historically but lack strong efficacy data for neuro-progression.
Surgical & Procedural Management
Corrective surgery for severe kyphoscoliosis (spinal fusion) or severe pes cavus (tendon transfers/osteotomies) to maintain sitting posture and comfort.
Patient Counseling & Advice
Discuss the progressive nature of the disease, the high likelihood of becoming wheelchair-bound, and the critical importance of regular cardiac monitoring. Provide genetic counseling for family planning.
Follow-Up & Monitoring Schedule
Annual ECG, echocardiogram, and Holter monitor to detect cardiomyopathy and arrhythmias. Annual HbA1c and vision/hearing screens. Regular neurologic and spine exams.
Preventive Strategies
Genetic counseling and prenatal diagnosis for at-risk couples.
Highly variable but generally correlates with the size of the GAA repeat expansion. Average life expectancy is roughly 40-50 years, with death predominantly resulting from cardiac arrhythmias or congestive heart failure.